Pacific Region Manages Dengue, Measles and Respiratory Outbreaks
As of 29 September 2026, public health agencies across the Pacific region are actively managing concurrent outbreaks of dengue fever, measles, and respiratory illnesses. According to surveillance data published by the Pacific Community, the Republic of the Marshall Islands, Samoa, and Vanuatu are directing vector control and vaccination responses against distinct dengue virus serotypes. Simultaneously, measles clusters in Australia and Papua New Guinea have triggered targeted immunization campaigns, while New Zealand reports declining yet elevated acute respiratory illness hospitalizations.
- Dengue outbreaks involving DENV-1 are active in the Marshall Islands, while DENV-1 and DENV-2 are active in Samoa and Vanuatu, prompting localized vector control and public outreach.
- Measles clusters in South Australia and Papua New Guinea have driven health authorities to issue red alerts and expand vaccination coverage for unimmunized populations.
- New Zealand’s influenza-positive SARI hospitalizations have dropped for four consecutive weeks but remain in the medium activity band, disproportionately affecting Pacific peoples.
Dengue Fever Outbreaks and Serotype Distribution in the Marshall Islands, Samoa, and Vanuatu
The Republic of the Marshall Islands Ministry of Health and Human Services reported 103 confirmed dengue positive specimens out of 268 tested in Majuro and Ebeye between 15 August and 19 September 2026. The 9th Outbreak Situation Report records six cumulative hospitalizations with zero deaths, while vector control operations—including chemical spraying and community clean-up campaigns—continue across schools and churches under an active red alert. Only the DENV-1 serotype has been detected in the territory.
In Samoa, the Ministry of Health reported 28 new dengue cases for EpiWeek 37, marking a 65 percent increase from the previous week. Since 1 January 2025, Samoa has recorded 20,260 clinically diagnosed cases, 5,540 laboratory-confirmed cases, and nine dengue-related deaths. Serotyping indicates that DENV-1 accounts for 52 percent and DENV-2 for 48 percent of cases, maintaining a blue alert status across the island nation.
Vanuatu’s National Surveillance Unit confirmed 150 total cases as of mid-September 2026, with transmission extending from Efate to Santo Island. Fourteen patients have required hospitalization and all have recovered and been discharged. Public health officials continue to monitor vector density while awaiting serotyping results for specimens gathered outside Port Vila.
Measles Clusters and Immunization Responses in Australia and Papua New Guinea
South Australia health authorities declared a measles cluster originating at Brighton Secondary School in Adelaide after an index case returned from overseas on 14 September 2026. SA Health confirmed a fifth case linked directly to this school setting, bringing the total number of measles cases in South Australia for 2026 to nine, compared to seven recorded throughout all of 2025. Exposure lists span 28 locations across Adelaide, prompting public health advisories for unimmunized individuals to monitor symptoms for 7 to 18 days post-exposure.
In Papua New Guinea, the National Department of Health weekly bulletin for EpiWeek 38 recorded 13 laboratory-confirmed measles cases year-to-date, with the National Capital District accounting for six of those infections. Acute fever and rash cases total 347, alongside 21 identified rubella cases and seven dual-positive infections. A targeted measles-rubella vaccination campaign is underway for children under seven years of age in affected districts.
Respiratory Illness Trends and Severe Acute Respiratory Infection Rates in New Zealand
New Zealand’s influenza-positive SARI hospitalisation rate in the Auckland region decreased for the fourth week ending 20 September 2026, settling into the medium activity band according to data from PHF Science. Test positivity fell from 50.9 percent to 33.3 percent, with influenza A subtypes A/H1 and A/H3 circulating concurrently. Surveillance indicates that Pacific peoples have experienced the highest cumulative rates of influenza, respiratory syncytial virus, and SARS-CoV-2-positive SARI hospitalizations throughout the year.
Clinical management of multi-pathogen epidemics requires coordinated surveillance and rapid deployment of preventive measures by regional health authorities. Patients presenting with persistent febrile illnesses or respiratory distress in affected zones should consult qualified medical professionals for diagnostic evaluation and supportive care.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.